Last reviewed 2026-04-23 · How we verify

CAIVT 10^5

MedImmune LLC · Phase 2 active Biologic

CAIVT 10^5 is a Virus vaccine Biologic drug developed by MedImmune LLC. It is currently in Phase 2 development for Respiratory syncytial virus infection.

CAIVT 10^5 is a live attenuated virus vaccine.

CAIVT 10^5 is a live attenuated virus vaccine. Used for Respiratory syncytial virus infection.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CAIVT 10^5
Sponsor	MedImmune LLC
Drug class	Virus vaccine
Modality	Biologic
Therapeutic area	Respiratory
Phase	Phase 2

Mechanism of action

It works by inducing an immune response against the virus, providing protection against infection.

Approved indications

Respiratory syncytial virus infection

Common side effects

Runny nose
Cough
Fever

Key clinical trials

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CAIVT 10^5 CI brief — competitive landscape report
CAIVT 10^5 updates RSS · CI watch RSS
MedImmune LLC portfolio CI

Frequently asked questions about CAIVT 10^5

What is CAIVT 10^5?

CAIVT 10^5 is a Virus vaccine drug developed by MedImmune LLC, indicated for Respiratory syncytial virus infection.

How does CAIVT 10^5 work?

CAIVT 10^5 is a live attenuated virus vaccine.

What is CAIVT 10^5 used for?

CAIVT 10^5 is indicated for Respiratory syncytial virus infection.

Who makes CAIVT 10^5?

CAIVT 10^5 is developed by MedImmune LLC (see full MedImmune LLC pipeline at /company/medimmune-llc).

What drug class is CAIVT 10^5 in?

CAIVT 10^5 belongs to the Virus vaccine class. See all Virus vaccine drugs at /class/virus-vaccine.

What development phase is CAIVT 10^5 in?

CAIVT 10^5 is in Phase 2.

What are the side effects of CAIVT 10^5?

Common side effects of CAIVT 10^5 include Runny nose, Cough, Fever.

Drug class: All Virus vaccine drugs
Manufacturer: MedImmune LLC — full pipeline
Therapeutic area: All drugs in Respiratory
Indication: Drugs for Respiratory syncytial virus infection

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing